Skip to main content
. 2022 Jan 31;6(3):774–784. doi: 10.1182/bloodadvances.2021006101

Figure 3.

Figure 3.

Proportion of concordance of humoral and cellular immune response to the mRNA-1273 vaccine according to baseline characteristics in patients diagnosed with hematologic malignancies. CR, complete response; PR, partial response; SD/PD, stable disease/progressive disease.